Return to Headlines
1257 views
Email RSS

OXiGENE has the Highest Upside Potential in the Biotechnology Industry (OXGN, PRAN, RXII, XOMA, AFFY)

Written on Thu, 07/01/2010 - 4:13am
By Chip Brian

Below are the top five companies in the Biotechnology industry as measured by the potential gains between the current stock price and the projected average analyst target.
OXiGENE (NASDAQ:OXGN) has a potential upside of 947.1% based on a current price of $0.38 and an average consensus analyst price target of $4.
Prana Biotechnology (NASDAQ:PRAN) has a potential upside of 614.3% based on a current price of $1.12 and an average consensus analyst price target of $8.
RXi Pharmaceuticals (NASDAQ:RXII) has a potential upside of 476.9% based on a current price of $2.6 and an average consensus analyst price target of $15.
XOMA (NASDAQ:XOMA) has a potential upside of 379.4% based on a current price of $0.41 and an average consensus analyst price target of $1.98.
Affymax (NASDAQ:AFFY) has a potential upside of 378.7% based on a current price of $5.98 and an average consensus analyst price target of $28.63.
SmarTrend is bearish on shares of AFFY and our subscribers were alerted to Sell on June 01, 2010 at $20.35. The stock has fallen 70.6% since the alert was issued.

Contact Chip Brian
Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.